PRRX1 and acute myeloid leukemia: Notably, Prrx1-CreERT2;Mettl3fl/fl mice had a significantly decreased survival time and shorter symptomatic AML latency than control mice (median survival 22 versus 24 days, P = 0.0020) (Fig. 2B).